Federal Awards · UNIVERSITY OF OKLAHOMA · Award

BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BI…

Research this with AI

Analyze this awardResearch incumbentExplore recompete potential

SmartSolo ChatGPT Claude Perplexity Grok Gemini

Ask AI researches this public topic. CaptureIQ qualifies the opportunity, manages the pursuit, and prepares review-ready materials.

Ready to pursue? Open in CaptureIQ.

Award details are derived from public USAspending.gov records linked to this contractor. Not a bid recommendation.

Award details

Award ID: 75N91023F00001
Contractor: UNIVERSITY OF OKLAHOMA
Awarding agency: Department of Health and Human Services
Sub-agency / office: National Institutes of Health
Award amount: $1,140,397
Period of performance: Sep 11, 2023 – Sep 10, 2027

Public award description

BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS TASK ORDER TITLE: COLORECTAL CANCER (CRC) PREVENTION BY TPST-1495 IN PIRC RAT MODEL

Most recent · Modification P00028 · Sep 17, 2026 · $-60,991 action obligation · 75N91023F00001

Modification P00009 · Jul 24, 2026 · $100,000 action obligation · 75N91023F00001

Modification P00008 · May 28, 2026 · $545,000 action obligation · 75N91023F00001

Modification P00024 · May 14, 2026 · $7,712,032 action obligation · 75N91023F00001

Modification P00003 · Apr 30, 2026 · $6,317 action obligation · 75N91023F00001

Modification P00006 · Apr 21, 2026 · $233,000 action obligation · 75N91023F00001

Modification P00007 · Sep 3, 2024 · $0 action obligation · 75N91023F00001

Modification 0 · Aug 30, 2023 · $10,979,211 action obligation · 75N91023F00001

Source: USAspending.gov

Related intelligence

Related Federal Awards

Same contractor · 75N91022F00002 — TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE · INFORMATION MANAGEMENT SERVICES, INC. · Department of Health and Human Services · $1,435,788
Same contractor · 75N91025F00001 — BASE IDIQ TITLE: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE… · INFORMATION MANAGEMENT SERVICES, INC. · Department of Health and Human Services · $1,234,179
Same contractor · 75N92023F00001 — STRONG HEART STUDY (SHS)- OKLAHOMA UNIVERSITY HEALTH CENTER (OUHSC) COORDINATING CENTER(CC) SUBTASK B.2 - P… · LEIDOS, INC. · Department of Health and Human Services · $1,218,378
Same contractor · 75N91022F00004 — CHEMOPREVENTION WITH MITOCHONDRIA-TARGETED HONOKIOL IN MOUSE MODELS OF LUNG CANCER: ADENOCARCINOMA AND SQUA… · INFORMATION MANAGEMENT SERVICES, INC. · Department of Health and Human Services · $1,201,554
Same contractor · 75N91026F00001 — TRIPLE NEGATIVE BREAST CANCER VACCINES · Department of Health and Human Services · $1,147,754
Same contractor · 75N91022F00003 — TASK ORDER TITLE: PREVENTING LUNG ADENOCARCINOMA (LUAD) USING TRAIL INDUCING AGENT, ONC201 BASE CONTRACT TI… · Department of Health and Human Services · $982,258

Browse federal awards · Browse contractors

Recompete monitoring

Awards approaching a documented period-of-performance end date. Related forecasts or opportunities are linked only when explicit references or strong deterministic signals match — expiration alone is not a confirmed recompete.

Period ends: Sep 10, 2027 (322 days)
Evidence status: FORECAST IDENTIFIED
Evidence score: 50 (deterministic, not pWin)
Forecast evidence: Matched forecast

Supporting evidence

FACT: Award period end date — 2027-09-10
FACT: Award start date — 2023-09-11
DERIVED: Days until period end — 322
FACT: Award recipient (incumbent on this award) — UNIVERSITY OF OKLAHOMA
FACT: Awarding agency — Department of Health and Human Services
FACT: Award amount (obligated/total as stored) — 1140397

Analyze in CaptureIQ (tenant recompete watch uses your workspace data separately).